Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes treated with a maximum of three different types of oral anti-diabetic drugs (OADs) (including traditional Chinese medicine which contains active ingredients of known OADs) for more than 6 months~* Unchanged total daily dose of at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) metformin for the last two months~* Unchanged total daily dose of at least half maximum recommended total daily dose of any insulin secretagogue for the last two months~* Insulin naive~* HbA1c between 7.0% and 10.0%~* FPG (fasting plasma glucose) equal to or above 6.1 mmol/L (110mg/dL)~* Body Mass Index (BMI) below 40.0 kg/m\^2~Exclusion Criteria:~* Treatment with any thiazolidinedione (TZD) and GLP-1 (glucagon like peptide-1) receptor antagonists during the last 3 months before Visit 1 in this trial~* Any disease or condition which the Investigator feels would interfere with the trial~* Any contraindication to metformin or glimepiride (according to local labelling)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 (Type: EXPERIMENTAL): 0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
- Insulin glargine (Type: ACTIVE_COMPARATOR): 0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride

Based on this trial design, predict the completion outcome and termination type (if applicable).